Atropine has been the apparent hero of myopia management since the 2006 ATOM1 study, and since then, low concentration 0.01% atropine has become the new hero and then fallen out of favour. This article describes how lower concentrations work to balance efficacy and side effects, which should we select now, and what newer research on formulations and combinations can tell us.
Retinal detachment is not a condition which only affects adults. This case of a 12-year-old high myope with an asymptomatic retinal detachment and hole forms the basis for discussion of factors, frequency of types and treatment outcomes in childhood retinal detachment. The myopia control strategy is also discussed.
Myopia control is vital for children with fast myopia progression. What are the key risk factors for faster myopia progression? What clinical findings indicate a more proactive myopia management strategy may be required? This case describes risk factors and evidence-based treatment options for fast myopia progressors.